Zurich Cantonal Bank’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Zurich Cantonal Bank’s Portfolio CBMG Stock Details CBMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-10,041	Closed	-$114K	–	2555
2017 Q4	$114K	Hold	10,041	–	–	﹤0.01%	1497
2017 Q3	$107K	Buy	+10,041	New	+$95K	﹤0.01%	1346
2017 Q2	–	Sell	-10,541	Closed	-$124K	–	2589
2017 Q1	$124K	Sell	10,541 -830	-7%	-$10.1K	﹤0.01%	1215
2016 Q4	$149K	Sell	11,371 -23,200	-67%	-$311K	﹤0.01%	1083
2016 Q3	$501K	Hold	34,571	–	–	0.01%	854
2016 Q2	$415K	Buy	34,571 +935	+3%	+$15K	0.01%	852
2016 Q1	$627K	Buy	33,636 +7,355	+28%	+$122K	0.01%	798
2015 Q4	$565K	Buy	26,281 +1,057	+4%	+$22.3K	0.01%	816
2015 Q3	$427K	Buy	25,224 +15,587	+162%	+$388K	0.01%	855
2015 Q2	$361K	Buy	9,637 +3,737	+63%	+$121K	0.01%	888
2015 Q1	$186K	Buy	+5,900	New	+$159K	﹤0.01%	931

Other funds holding CBMG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TEE

Tibra Equities Europe London, United Kingdom $90.4M AUM 37.81% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Zurich Cantonal Bank's CBMG Position: Q1 2018 in Review

Zurich Cantonal Bank sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2018, closing a stake of 10,041 shares — an estimated $114K sold.

Zurich Cantonal Bank first reported a position in CBMG in Q1 2015 and held it in 11 quarters. The position peaked at $627K in Q1 2016. 25 funds tracked by Wall St. Rank hold CBMG as of Q1 2018.

Zurich Cantonal Bank reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2018 after selling out during the quarter.
Zurich Cantonal Bank sold 10,041 Cellular Biomedicine Group, Inc. shares in Q1 2018, an estimated $114K.
Zurich Cantonal Bank first reported a position in Cellular Biomedicine Group, Inc. in Q1 2015 and held it in 11 quarters.
Zurich Cantonal Bank's Cellular Biomedicine Group, Inc. position peaked at $627K in Q1 2016.
25 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2018.

Based on Zurich Cantonal Bank's 13F filing for Q1 2018, filed 3 May 2018.